IOMAI was a Biotech company founded in 1997 by Gregory Glenn M.D. of the Walter Reed Army Institute of Research

Walter Reed Army Institute of Research

This article is about the U.S. Army medical research institute . Otherwise, see Walter Reed .The Walter Reed Army Institute of Research is the largest biomedical research facility administered by the U.S. Department of Defense...

 and Dean Lewis, a World Bank

World Bank

The World Bank is an international financial institution that provides loans to developing countries for capital programmes.The World Bank's official goal is the reduction of poverty...

 employee. The company was the first to develop the concept of transcutaneous immunization, delivery of vaccines to the skin using a patch or similar method. This provided a means to stimulate robust immune responses safely as the skin patch-based immunization targeted Langerhans cells in the skin. The patch technology underwent extensive evaluation in the context of a traveler's diarrhea vaccine which entered Phase 3 pivotal trials in 2009. IOMAI was acquired by Intercell

Intercell

Intercell AG is a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases...

in 2008 and the technology was the subject of a development license to GSK in 2009. Dr. Glenn pioneered needle free delivery to the skin and spawned general interest in skin-targeting vaccine technologies, including intradermal delivery and the use of the heat labile toxin as an adjuvant and the adjuvant patch.